Danielle Bello, MD
Surgical Oncology · New York, NYNPI 1780811133
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $157 of the $176 with a category attached, or 89.1%. Medtronic accounts for 89.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for surgical oncology clinicians in NY, where the typical reported total is $1,068.
Across 2 payments — averaging $88.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$157
- Davol Inc.$19
Across 1 payment — averaging $251,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$252K
What the payments were for
- Food & beverage$15789%
- Education$1911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $157 |
| Davol Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Signia$157
How this compares
$176 in reported general payments places this provider in the 25th percentile of 173 surgical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefadroxil | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in New York
- Sheldon FeldmanNew York$97K
- Kepal PatelNew York$94K
- George PlitasNew York$39K
- James ParkNew York$28K
- Michael LoweNew York$20K
- Scott HananNew York$15K
- Marcovalerio MelisNew York$12K
- Kevin SoaresNew York$10K
- Jennifer CracchioloNew York$9K
- Bert PetersenNew York$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.